L-carnitine (4-N-trimethylammonium-3-hydroxybutyric acid) is the physiologically active form of carnitine and is a natural compound that has been shown to exhibit antioxidant activity. L-carnitine is used as a supplementary treatment in patients with cirrhosis with hepatic encephalopathy, hyperammonemia or muscle cramps. In the present study, the effect of L-carnitine supplementation on health-related quality of life in 30 patients with cirrhosis was prospectively examined. L-carnitine (1,800 mg/day) was administered orally for 6 months. To assess the effects of L-carnitine on chronic fatigue, patients filled out a self-report questionnaire regarding their physical and mental health. The levels of total and free carnitine, and acylcarnitine were found to be significantly higher 1, 3 and 6 months after therapy initiation compared with before treatment. Serum albumin levels were significantly increased 3 and 6 months after initiation of therapy. L-carnitine supplementation significantly increased the BAP/d-ROM ratio, a marker of antioxidant status in patients with cirrhosis. Changes in serum carnitine concentrations were positively correlated with changes in serum albumin levels (R2=0.369; P=0.012), but not with changes in serum ammonia levels (R2= 0.005; P=0.78). Total and mental health scores improved significantly, and physical scores improved marginally 3 and 6 months after initiation of L-carnitine. These findings may be attributed to the enhanced serum albumin levels and oxidative stress rather than the reduced serum ammonia levels. Based on these results, it is suggested that L-carnitine can potentially alleviate chronic fatigue, along with the increased BAP/d-ROM ratio, which were involved in increased oxidative stress in patients with cirrhosis. The specific mechanisms by which L-carnitine ameliorates chronic fatigue is not fully understood and requires further investigation.
L-carnitine (4-N-trimethylammonium-3-hydroxybutyric acid), the biologically active form of carnitine, is synthesized from the essential amino acids, methionine and lysine in certain organs, including the liver (1). Serum L-carnitine concentration varies according to the tissue type (2), nutritional status (3,4) and the quality of the foodstuff (5). L-carnitine regulates the cellular process of generating energy by transferring acyl groups from the cytoplasm to the mitochondrial matrix for β-oxidation (6). L-carnitine deficiency has been demonstrated to reduce the availability of energy in the liver and is associated with impairments in various aspects of energy metabolism, including utilization and accumulation of carbohydrate and lipids in liver cirrhosis (7,8). Several studies have described the ability of L-carnitine to reduce serum ammonia concentration in clinical trials (9,10). L-carnitine supplementation also reduces the rate of loss of muscle mass (11) and muscle cramps (12) in patients with liver cirrhosis. Intravenous L-carnitine prevents the recurrence of overt hepatic encephalopathy in patients with decompensated cirrhosis (13). Recently, a meta-analysis showed that L-carnitine administration produces favorable effects based on the levels of biochemical markers in patients with cirrhosis (14). Furthermore, its adverse effects are minimal, but may include abdominal pain, nausea, diarrhea and a fishy smell emanating for the patient (15). To the best of our knowledge, there are no studies which have addressed the effect of L-carnitine on health-related quality of life in patients with cirrhosis. The aim of the present study was to evaluate the effects of L-carnitine on chronic fatigue in patients with cirrhosis through the use of self-report questionnaires.
Materials and methodsPatients
The present study was designed as a clinical trial to prospectively assess the effect of L-carnitine supplementation on chronic fatigue in patients with cirrhosis. The diagnosis of cirrhosis was based on histological examination of biopsy specimens, transient elastography, laboratory tests or imaging findings. Exclusion criteria were evidence of hepatocellular carcinoma, human immunodeficiency virus infection, pregnancy or severe cardiac, pulmonary, or renal diseases. A total of 41 patients with cirrhosis who visited the Department of Gastroenterology in Bellland General Hospital (Osaka, Japan), were asked to participate between April and September 2013 (Fig. 1). Of the 41 patients, 8 patients were excluded as they met at least one of the exclusion criteria, and 3 patients refused to participate; thus, a total of 30 patients were enrolled in the present study. The recruited cohort consisted of 30 patients (median age 69 years; age range, 43-78 years) with 19 (63.3%) men and 11 (36.7%) women. Patients took 600 mg (as two 300 mg tablets) of levocarnitine chloride (L-carnitine; Otsuka Pharmaceutical Co., Ltd.) three times a day (total daily dose, 1,800 mg) for 6 months. Blood samples were collected before treatment and 1, 3 and 6 months after L-carnitine supplementation was initiated, to measure the concentrations of several biochemical parameters, free and total carnitine, and acylcarnitine levels. Multiple factors affect the accuracy of ammonia levels. The patients were told not to exercise or smoke cigarettes 12 h before the fasting blood test was performed. The level of fasting venous ammonia was measured. The blood samples were immediately placed on ice after collection and was centrifuged within 15 min of collection, as described previously (16). None of the patients recruited in the final cohort were prescribed either cyanide, carbamazepine, valproic acid or iron, which can cause secondary hyperammonemia as a result of disruption of mitochondrial pathways (17,18). The initial version of Child-Pugh score, included two continuous variables (bilirubin and albumin) and three discrete (quantitative) variables (ascites, encephalopathy and nutritional status) (19). The selection of these five variables, as well as the cut-off values for bilirubin and albumin were empirical. The five variables and their respective cut-off values were arranged so as to define three distinct groups of increasing severity (A, B and C). Model For End-Stage Liver Disease (MELD) scores had been originally created with the aim of predicting survival after transjugular intrahepatic portosystemic shunt. The score (the ancestor of the current MELD score), derived from a survival function, was calculated as follows: R=0.957 Loge(creatinine [mg/dl])+0.378 Loge(bilirubin [mg/dl])+1.120 loge (Prothrombin Time-International Normalized Ratio)+0.643 (cause of cirrhosis). Before and after L-carnitine supplementation, patients were asked to complete the Chronic Fatigue Questionnaire (20). The severity of fatigue was reflected in self-reported ratings, based on daily activities and was represented by the performance status score (21,22). Informed consent was obtained from all participants before the initiation of the study. The present study was approved by the Human Ethics Review Committee of Bellland General Hospital (approval no. 2015-0004) and was performed in accordance with the Declaration of Helsinki (23). Subjects were monitored for safety and tolerance of L-carnitine during the course of the study.
Measurement of oxidative stress markers [d-reactive oxygen metabolites (ROMs)] and antioxidant capacity [biological antioxidant potential (BAP)]
Measurement of oxidative stress markers was performed by measuring oxidative stress in vivo with simple and accurate tests, d-ROMs-derived compounds and BAP test. The collected samples were immediately centrifuged at 3,000 x g at 4˚C for 10 min to separate the serum. The separated samples were stored in a freezer at -20˚C until further use. Before the assay was initiated, serum levels of d-ROMs and BAP were measured using commercial kits (Diacron International: Cat. nos. AT3274 and BR4873, respectively) on an Olympus AU640 (Olympus, Japan) according to manufacturer's protocol (24). The results of the d-ROMs analysis are expressed in Carratelli units (U.Carr), where 1 U.Carr corresponds to 0.8 mg/l H2O2. The results of the BAP analysis are expressed in µmol/l of the reduced ferric ions (25,26). Antioxidant/oxidant (BAP/dROMs) ratio was calculated to express relative antioxidant capacity.
Chronic Fatigue Questionnaire
Patients' health status was quantified using the Chronic Fatigue Questionnaire at four different time points: Before treatment, and 1, 3 and 6 months after the initiation of treatment. All patients enrolled in the present study completed the Chronic Fatigue Questionnaire, a 20-item self-report questionnaire used to examine physical and mental functioning, originally produced by Kuratsune et al (27) and Mizuno et al (28). All items were scored from 0-4; the physical health subscale and the mental health subscale each had 10 items. The physical and mental health scores reflected the mental and physical fitness performance, respectively. To calculate the total score, the scores of each item were added; thus the total score ranged from 0-40 points, with higher scores indicating greater fatigue and/or greater effects of fatigue on quality of life.
Statistical analysis
Numerical variables were calculated as the mean ± standard deviations. Quantitative parameters were compared using a one-way ANOVA with a post-hoc Tukey's tests. Spearman's rank correlation analysis was used to determine correlations. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS version 20.0 (IBM, Corp.).
ResultsPatient characteristics
The characteristics of the patients are listed in Table I. The recruited cohort consisted of 30 patients. The cause of liver disease was hepatitis C viral infection in 14 patients, hepatitis B viral infection in 2 patients, alcohol abuse in 9 patients, and other disorders, including primary biliary cholangitis, autoimmune hepatitis and idiopathic causes in 5 patients. The number of patients with Child-Pugh classifications (19) of A, B and C were 18, 10 and 2, respectively. The median serum level of ammonia was 91.0±52.0 µg/dl, and that of albumin was 3.3±0.5 g/dl. No adverse reactions attributable to L-carnitine administration were observed.
Effects of 6-month of L-carnitine supplementation on serum levels of total carnitine, free carnitine and acylcarnitine
The levels of total carnitine, free carnitine and acylcarnitine were significantly higher 1, 3 and 6 months after therapy initiation compared with before treatment was initiated. The mean serum levels of total carnitine were 66.1±10.5 µmol/l before treatment, 108.2±25.2 µmol/l after 1 month of treatment (P<0.05), 122.0±21.2 µmol/l after 3 months (P<0.05) and 117.2±12.2 µmol/l after 6 months (P<0.05; Fig. 2A). The mean serum levels of free carnitine were 52.4±9.1 µmol/l before treatment, 83.8±15.3 µmol/l after 1 month (P<0.05), 93.2±17.1 µmol/l after 3 months (P<0.05) and 87.5±16.2 µmol/l after 6 months (P<0.05; Fig. 2B). Mean serum levels of acylcarnitine were 14.1±3.1 µmol/l before treatment, 24.5±10.5 µmol/l after 1 month (P<0.05), 29.1±8.3 µmol/l after 3 months (P<0.05) and 29.4±8.5 µmol/l after 6 months (P<0.05; Fig. 2C).
Effects of 6-month L-carnitine supplementation on serum levels of albumin and ammonia
Serum albumin levels did not change significantly 1 month after L-carnitine therapy was initiated, but they were significantly higher after 3 and 6 months of supplementation compared with before treatment initiation. Mean serum levels were 3.2±0.5 µg/dl before treatment, 3.3±0.4 µg/dl after 1 month (P=0.78), 3.4±0.3 µg/dl after 3 months (P<0.05) and 3.6±0.3 µg/dl after 6 months (P<0.05; Fig. 3A). In all patients, serum ammonia levels did not change significantly 1 month after L-carnitine therapy was initiated, but they were significantly higher 3 and 6 months after therapy initiation compared with before treatment initiation. Mean serum ammonia levels were 101±40 µg/dl before treatment, 78±35 µg/dl after 1 month (P<0.05), 80±30 µg/dl after 3 months (P<0.05) and 56.5±31 µg/dl after 6 months (P<0.05; Fig. 3B).
Effects of 6-month L-carnitine supplementation on Child-Pugh and MELD scores
L-carnitine supplementation did not have any significant effect on Child-Pugh or MELD scores. The Child-Pugh score was 7.3±1.4 before treatment, 7.2±1.5 after 1 month (P=0.58), 7.2±1.6 after 3 months (P=0.38) and 7.2±1.9 after 6 months (P=0.32; Fig. 4A). The MELD score was 6.6±0.9 before treatment, 6.7±0.9 after 1 month (P=0.32), 6.6±1.1 after 3 months (P=0.74) and 6.8±1.5 after 6 months (P=0.65; Fig. 4B).
Effect of L-carnitine supplementation on chronic fatigue
The total scores on the Chronic Fatigue Questionnaire before treatment and after 1 month of L-carnitine supplementation did not differ significantly, but were significantly decreased after 3 and 6 months. The mean total scores were 14.7±6.0 before treatment, 14.5±6.0 after 1 month (P>0.05), 10.3±5.0 points after 3 months (P<0.05) and 8.74±5.0 after 6 months (P<0.05; Fig. 5A). On the physical subscale, scores were significantly decreased 3 and 6 months after therapy initiation; mean scores were 7.37±4.5 points before treatment, 7.27±3.0 points after 1 month (P>0.05), 5.17±3.0 after 3 months (P<0.05) and 4.37±4.0 after 6 months (P<0.05; Fig. 5B). On the mental subscale, the scores were significantly decreased 3 and 6 months after therapy initiation; mean scores were 7.42±3.0 before treatment, 7.37±3.0 points after 1 month (P>0.05), 5.22±3.2 after 3 months (P<0.05) and 4.43±3.1 after 6 months (P<0.05; Fig. 5C).
Correlation of changes in total carnitine levels with changes in serum albumin levels and changes in serum ammonia levels
Changes in serum carnitine concentrations were positively correlated with changes in serum albumin levels (R2=0.369; P=0.012), but not with changes in serum ammonia levels (R2=0.005; P=0.78; Fig. 6A and B).
Effects of 6-month L-carnitine supplementation on the d-ROMs/BAP ratio
L-carnitine supplementation did not significantly affect the serum d-ROM levels after 1 month; however, serum d-ROM levels were significantly lower 3 and 6 months after therapy initiation compared with before the treatment. Mean levels were 246.1±46.2 U.Carr before treatment, 225.2±50.6 U.Carr after 1 month (P=0.67), 210.9±20.3 U.Carr after 3 months (P<0.05) and 205.8±30.5 U.Carr after 6 months (P<0.05; Fig. 7A). However, L-carnitine supplementation did not have any significant effect on serum BAP levels. Mean levels were 2,100±322 µmol/l before treatment, 2,095±310 µmol/l after 1 month (P=0.52), 2,152±390 µmol/l after 3 months (P=0.43) and 2,120±385 µmol/l after 6 months (P=0.28; Fig. 7B). There was no significant effect of L-carnitine supplementation after 1 month on the d-ROMs/BAP ratio, but the d-ROMs/BAP ratio was significantly higher 3 and 6 months after therapy initiation compared with before treatment initiation. The ratio of d-ROMs/BAP was 8.5±2.0 before treatment, 9.3±2.2 after 1 month (P=0.21), 10.2±1.9 µg/dl after 3 months (P<0.05) and 10.3±1.5 after 6 months (P<0.05; Fig. 7C).
Discussion
L-carnitine is a nutrient prerequisite for energy generation in vital organs, including the liver, kidneys and brain (29,30). Carnitine deficiency occurs in various disorders, such as malnutrition, liver cirrhosis, endocrine disorders and end-stage renal disease treated with hemodialysis, all of which are considered to affect health-related quality of life (31,32). To the best of our knowledge, the present study is the first prospective study to show that 1,800 mg/day L-carnitine supplementation for 6 months exhibited favorable effects on chronic fatigue in patients with cirrhosis. L-carnitine increased carnitine profiles, serum albumin levels, the ratio of BAP/d-ROM and decreased serum ammonia levels. L-carnitine increases carnitine palmitoyl transferase activity, which reflects mitochondrial fatty acid oxidation resulting in increased acylcarnitine levels (33). As changes in serum carnitine concentrations were positively correlated with changes in serum albumin levels, but not with changes in serum ammonia levels, this suggests that L-carnitine ameliorated chronic fatigue by attenuating oxidative stress.
A meta-analysis revealed that supplemental intake of 4,000 mg L-carnitine increases serum albumin levels and ameliorates serum ammonia levels in patients with hepatic encephalopathy (14). L-carnitine supplementation reduced the levels of ammonia in patients with cirrhosis with physiological blood carnitine levels (34), suggesting that increased quantities of carnitine is required for patients with cirrhosis compared with the healthy individuals, and that patients may have exhibited a relative carnitine deficiency. In contrast, 600 mg oral L-carnitine daily was reported to counteract the reduction in serum albumin levels 1 week after transarterial chemoembolization (TACE) in patients with cirrhosis (35). These findings suggest that higher doses of L-carnitine supplementation may not be necessary for producing the therapeutic benefits as the homeostatic control of serum L-carnitine levels is tight and subtle (15). In the present study, it was shown that both Child-Pugh and MELD scores did not change significantly during the 6-month follow-up. However, L-carnitine supplementation maintains the levels of branched-chain amino acids for albumin synthesis, and this has been shown to improve Child-Pugh scores following TACE (35). The discrepancy may be partly explained by the differences in patient characteristics between the two studies. A systematic review and meta-analysis revealed beneficial effects of L-carnitine on serum albumin levels in patients with cirrhosis (14). However, L-carnitine did not increase the serum albumin levels in patients with nonalcoholic steatohepatitis, whose serum albumin levels were already relatively high (36). These data reinforce the fact that L-carnitine improves serum albumin levels in patients with cirrhosis, which is frequently complicated by hypoalbuminemia (37).
The complication of minimal encephalopathy may cause mental disorders in patients with cirrhosis. Administration of acetyl-L-carnitine, an acetylated form of L-carnitine improved the mental status to normal levels and resolved hyperammonemia in a patient on chronic hemodialysis who exhibited elevated serum ammonia levels and altered mental status (38). With acetyl-L-carnitine, a significant decrease in serum ammonia levels was observed in patients with cirrhosis, along with a significant improvement in mental function (39). Patients with hepatic encephalopathy treated with L-carnitine showed significant improvements with regard to mental fatigue (40). An intensity-dependent relationship was found between ammonia levels and exercise, which suggested that ammonia accumulation exhibits a pivotal role in both physical and mental fatigue (41). Malaguarnera et al (42) demonstrated that in patients with minimal hepatic encephalopathy, acetyl-L-carnitine improved the quality of life by reducing serum albumin levels. However, L-carnitine did not exert considerable effects on ammonia levels 3 months after L-carnitine supplementation (42). The causes of differences in serum carnitine profiles between the studies are unclear. However, one possible explanation is the differences in the causes of liver cirrhosis and in the functional reserve capacities in patients (43,44). Furthermore, in the present study, changes in total carnitine levels were not significantly correlated with changes in ammonia levels. These findings suggest that the favorable effects of L-carnitine on chronic fatigue in patients with cirrhosis cannot be attributed to improvements in serum ammonia levels.
The mechanism underlying the favorable effects of L-carnitine on chronic fatigue remain unclear. L-carnitine supplementation increases albumin levels in patients with cirrhosis. Patients receiving L-carnitine treatment showed improvements in daily activity performance levels and the performance efficiency of high-intensity muscular exercise, through the regulation of mitochondrial homeostasis (45). More recent evidence has suggested a close association between chronic fatigue and oxidative stress (46). In the present study, it was shown that L-carnitine supplementation increased the BAP/d-ROM ratio with serum albumin levels in patients with cirrhosis. Albumin is involved in several bioactive functions, such as antioxidant activity (47). Furthermore, serum albumin reportedly decreased oxidative stress by inhibiting the activation of nicotinamide adenine dinucleotide phosphate oxidase in human vascular smooth muscle (48). In addition, L-carnitine supplementation augmented fat oxidation and energy expenditure during prolonged exercise, which therefore spares glycogen stores and delays the onset of fatigue (39). These findings suggest that L-carnitine supplementation can potentially ameliorate chronic fatigue by attenuating oxidative stress (49). However, the exact mechanisms by which L-carnitine ameliorates chronic fatigue requires further investigation.
Several limitations associated with the present study must be mentioned. First, it was not possible to compare patients who received L-carnitine treatment with patients who did not. Second, the relationship between physical function and skeletal muscle mass were not assessed, which may explain the effect of L-carnitine on sarcopenia. Furthermore, the sample size was relatively small. A future study with a larger cohort is required to confirm the results of the present study. However, the present study is the first prospective clinical trial in which the beneficial effects of L-carnitine supplementation on physical and mental functional abilities in patients with cirrhosis and chronic fatigue were assessed through the use of a self-report questionnaire. The results showed that improvement in carnitine profiles were accompanied by increases in serum albumin levels, but not changes in serum ammonia levels. This suggests that L-carnitine ameliorates chronic fatigue by attenuating oxidative stress. L-carnitine alleviated chronic fatigue and increased serum albumin levels, which are recognized markers of antioxidant status in patients with cirrhosis. Nevertheless, larger studies are required to evaluate the effects of carnitine on health-related quality of life in patients with cirrhosis and investigate the exact mechanisms by which L-carnitine ameliorates chronic fatigue.
Acknowledgements
The authors would like to thank Ms Nakai (Nara Medical University) for assistance in collecting the clinical data.
Funding
This study was partially supported by Grants-in-Aid for Scientific Research from Nara Medical University (grant no. 15K08077).
Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
Authors' contributions
SSat, MF, SSai, HK, KKa, HT, NS, YS, KKi, KM, TAk, NH and TAn performed the data analysis. AM, HY and TN made substantial contributions to the conception and design of the study, as well as analysis and interpretation of the data. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Informed consent was obtained from all participants before the initiation of the study. This study was approved by the Human Ethics Review Committee of Bellland General Hospital (Osaka, Japan), (approval no. 2015-0004) and was performed in accordance with the Declaration of Helsinki.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesOney-BirolSExogenous L-carnitine promotes plant growth and cell division by mitigating genotoxic damage of salt stressSci Rep91722920193175424710.1038/s41598-019-53542-2RinaudoMTCurtoMBrunoRPiccininiMMarinoCAcid soluble, short chain esterified and free carnitine in the liver, heart, muscle and brain of pre and post hatched chicksInt J Biochem2359651991202229710.1016/0020-711x(91)90009-cKhanLBamjiMSTissue carnitine deficiency due to dietary lysine dificiency: Triglyceride accumulation and concomitant impairment in fatty acid oxidationJ Nutr1092431197943021110.1093/jn/109.1.24ReboucheCJCarnitine function and requirements during the life cycleFASEB J63379338619921464372CimminoAAndolfiAZonnoMCTroiseCSantiniATuziAVurroMAshGEvidenteAPhomentrioloxin: A phytotoxic pentasubstituted geranylcyclohexentriol produced by Phomopsis sp., a potential mycoherbicide for Carthamus lanatus BiocontrolJ Nat Prod751130113720122269448910.1021/np300200jLongoNFrigeniMPasqualiMCarnitine transport and fatty acid oxidationBiochim Biophys Acta18632422243520162682877410.1016/j.bbamcr.2016.01.023RingseisRKellerJEderKRole of carnitine in the regulation of glucose homeostasis and insulin sensitivity: Evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiencyEur J Nutr5111820122213450310.1007/s00394-011-0284-2IrvineKMRatnasekeraIPowellEEHumeDACauses and consequences of innate immune dysfunction in cirrhosisFront Immunol1029320193087316510.3389/fimmu.2019.00293MalaguarneraMVacanteMMottaMGiordanoMMalaguarneraGBellaRNunnariGRampelloLPennisiGAcetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: A randomized and controlled clinical trialMetab Brain Dis2628128920112187012110.1007/s11011-011-9260-zCecereACiaramellaFTancrediLRomanoCGattoniAEfficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis: Results of a randomised trialClin Drug Investig22 (Suppl 1)S7S1420022331543010.2165/00044011-200222001-00002HiramatsuAAikataHUchikawaSOhyaKKodamaKNishidaYDaijoKOsawaMTeraokaYHondaFLevocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosisHepatol Commun334835520193085914710.1002/hep4.1309NakanishiHKurosakiMTsuchiyaKNakakukiNTakadaHMatsudaSGondoKAsanoYHattoriNTamakiNL-carnitine reduces muscle cramps in patients with cirrhosisClin Gastroenterol Hepatol131540154320152549681610.1016/j.cgh.2014.12.005TajiriKFutsukaichiYKobayashiSYasumuraSTakaharaTMinemuraMSugiyamaTL-carnitine for the treatment of overt hepatic encephalopathy in patients with advanced liver cirrhosisJ Nutr Sci Vitaminol (Tokyo)6432132820183038162110.3177/jnsv.64.321AbbasnezhadAChoghakhoriRKashkooliSAlipourMAsbaghiOMohammadiREffect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy: A systematic review and meta-analysisJ Gastroenterol Hepatol342062207020193125446910.1111/jgh.14765ShangRSunZLiHEffective dosing of L-carnitine in the secondary prevention of cardiovascular disease: A systematic review and meta-analysisBMC Cardiovasc Disord148820142504403710.1186/1471-2261-14-88HowanitzJHHowanitzPJSkrodzkiCAIwanskiJAInfluences of specimen processing and storage conditions on results for plasma ammoniaClin Chem3090690819846723050BajajJSCordobaJMullenKDAmodioPShawcrossDLButterworthRFMorganMYInternational Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN)Review article: The design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statementAliment Pharmacol Ther3373974720112130640710.1111/j.1365-2036.2011.04590.xMichalakARoseCButterworthJButterworthRFNeuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failureHepatology249089131996885519610.1002/hep.510240425PengYQiXGuoXChild-pugh versus MELD score for the assessment of prognosis in liver cirrhosis: A systematic review and meta-analysis of observational studiesMedicine (Baltimore)95e287720162693792210.1097/MD.0000000000002877TanakaSKuratsuneHHidakaYHakariyaYTatsumiKITakanoTKanakuraYAminoNAutoantibodies against muscarinic cholinergic receptor in chronic fatigue syndromeInt J Mol Med12225230200312851722OkadaTTanakaMKuratsuneHWatanabeYSadatoNMechanisms underlying fatigue: A voxel-based morphometric study of chronic fatigue syndromeBMC Neurol41420041546181710.1186/1471-2377-4-14MatsudaYMatsuiTKataokaKFukadaRFukudaSKuratsuneHTajimaSYamagutiKKatoYHKiriikeNA two-year follow-up study of chronic fatigue syndrome comorbid with psychiatric disordersPsychiatry Clin Neurosci6336537320091956676910.1111/j.1440-1819.2009.01954.xGeneral Assembly of the World Medical AssociationWorld Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjectsJ Am Coll Dent811418201425951678MorimotoMHashimotoTTsudaYKitaokaTKyotaniSEvaluation of oxidative stress and antioxidant capacity in healthy childrenJ Chin Med Assoc8265165420193089326210.1097/JCMA.0000000000000045CeliPSullivanMEvansDThe stability of the reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests on stored horse bloodVet J18321721820101901070310.1016/j.tvjl.2008.09.018BergamiRMaranesiMMarchettiMSangiorgiZTolomelliBInfluence of dietary n-3 polyunsaturated fatty acids on plasma lipemic effect of vitamin B6 deficiencyInt J Vitam Nutr Res6931532119991052677510.1024/0300-9831.69.5.315KuratsuneHYamagutiKLindhGEvengårdBHagbergGMatsumuraKIwaseMOnoeHTakahashiMMachiiTKanakuraYBrain regions involved in fatigue sensation: Reduced acetylcarnitine uptake into the brainNeuroimage171256126520021241426510.1006/nimg.2002.1260MizunoKTanakaMNozakiSMizumaHAtakaSTaharaTSuginoTShiraiTKajimotoYKuratsuneHKajimotoOWatanabeYAntifatigue effects of coenzyme Q10 during physical fatigueNutrition2429329920081827233510.1016/j.nut.2007.12.007MalaguarneraMCarnitine derivatives: Clinical usefulnessCurr Opin Gastroenterol2816617620122233356210.1097/MOG.0b013e3283505a3bKendlerBSCarnitine: An overview of its role in preventive medicinePrev Med153733901986353208710.1016/0091-7435(86)90005-8MalaguarneraMAcetyl-L-carnitine in hepatic encephalopathyMetab Brain Dis2819319920132338962010.1007/s11011-013-9376-4GonwaTAWadeiHMKidney disease in the setting of liver failure: Core curriculumAm J Kidney Dis 2013621198121220132410012910.1053/j.ajkd.2013.07.017FlanaganJLSimmonsPAVehigeJWillcoxMDGarrettQRole of carnitine in diseaseNutr Metab (Lond)73020102039834410.1186/1743-7075-7-30ShirakiMShimizuMMoriwakiHOkitaKKoikeKCarnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patientsHepatol Res4732132720172725413310.1111/hepr.12750HassanATsudaYAsaiAYokohamaKNakamuraKSujishiTOhamaHTsuchimotoYFukunishiSAbdelaalUMArafaUAEffects of oral L-carnitine on liver functions after transarterial chemoembolization in intermediate-stage HCC patientsMediators Inflamm201560821620152666415110.1155/2015/608216MalaguarneraMGarganteMPRussoCAnticTVacanteMMalaguarneraMAvitabileTLi VoltiGGalvanoFL-carnitine supplementation to diet: A new tool in treatment of nonalcoholic steatohepatitis-a randomized and controlled clinical trialAm J Gastroenterol1051338134520102006855910.1038/ajg.2009.719SoetersPBWolfeRRShenkinAHypoalbuminemia: Pathogenesis and clinical significanceJPEN J Parenter Enteral Nutr4318119320193028875910.1002/jpen.1451DaVanzoWJUllianMEL-carnitine administration reverses acute mental status changes in a chronic hemodialysis patient with hepatitis C infectionClin Nephrol57402405200212036203StephensFBConstantin-TeodosiuDGreenhaffPLNew insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscleJ Physiol58143144420071733199810.1113/jphysiol.2006.125799MalaguarneraMGarganteMPCristaldiEVacanteMRisinoCCammalleriLPennisiGRampelloLAcetyl-L-carnitine treatment in minimal hepatic encephalopathyDig Dis Sci533018302520081835753010.1007/s10620-008-0238-6MalaguarneraMVacanteMGiordanoMPennisiGBellaRRampelloLMalaguarneraMLi VoltiGGalvanoFOral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled studyAm J Clin Nutr9379980820112131083310.3945/ajcn.110.007393MalaguarneraMBellaRVacanteMGiordanoMMalaguarneraGGarganteMPMottaMMistrettaARampelloLPennisiGAcetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathyScand J Gastroenterol4675075920112144342210.3109/00365521.2011.565067AmodioPAngeliPMerkelCMenonFGattaAPlasma carnitine levels in liver cirrhosis: Relationship with nutritional status and liver damageJ Clin Chem Clin Biochem286196261990198122210.1515/cclm.1990.28.9.619D'ArienzoAMatteraDAmbrogioGDurantiLZeuliLMazzaccaGHypercarnitinemia in cirrhosisHepatology53431985397996510.1002/hep.1840050237GimenesACBravoDMNapolisLMMelloMTOliveiraASNederJANeryLEEffect of L-carnitine on exercise performance in patients with mitochondrial myopathyBraz J Med Biol Res4835436220152571488210.1590/1414-431X20143467LeeJSKimHGLeeDSSonCGOxidative stress is a convincing contributor to idiopathic chronic fatigueSci Rep81289020183015062010.1038/s41598-018-31270-3SitarMEAydinSCakatayUHuman serum albumin and its relation with oxidative stressClin Lab59945952201324273915KinoshitaHWatanabeKAzmaTFengGGAkahoriTHayashiHSatoMFujiwaraYWakatsukiAHuman serum albumin and oxidative stress in preeclamptic women and the mechanism of albumin for stress reductionHeliyon3e0036920172880869410.1016/j.heliyon.2017.e00369MalaguarneraMPistoneGAstutoMVecchioIRaffaeleRLo GiudiceERampelloLEffects of L-acetylcarnitine on cirrhotic patients with hepatic coma: Randomized double-blind, placebo-controlled trialDig Dis Sci512242224720061708025410.1007/s10620-006-9187-0
Schematic of the study protocol. Of the 41 prospective patients with cirrhosis, 30 met the inclusion criteria and agreed to participate. Patients were treated for 6 weeks with 1,800 mg of oral L-carnitine per day. Blood samples were tested, and patients filled in the Chronic Fatigue Questionnaire 1, 3 and 6 weeks after treatment initiation.
Changes in carnitine profiles during L-carnitine supplementation in patients with cirrhosis. After 1, 3 and 6 months of L-carnitine treatment, levels of (A) total carnitine, (B) free carnitine and (C) acylcarnitine were significantly higher compared with before treatment. Total carnitine levels were 66.1±10.5 µmol/l before treatment, 108.2±25.2 µmol/l after 1 month, 122.0±21.2 µmol/l after 3 months and 117.2±12.2 µmol/l after 6 months. Free carnitine levels were 52.4±9.1 µmol/l before treatment, 83.8±15.3 µmol/l after 1 month, 93.1±17.1 µmol/l after 3 months and 87.5±16.2 µmol/l after 6 months. Acylcarnitine levels were 14.1±3.1 µmol/l before treatment, 24.5±10.5 µmol/l after 1 month, 29.2±8.3 µmol/l after 3 months and 29.4±8.5 µmol/l after 6 months. The gray area indicates the physiological range. *P<0.05.
Changes in serum albumin and ammonia levels during L-carnitine supplementation in patients with cirrhosis. (A) L-carnitine supplementation for 3 and 6 months significantly increased serum albumin levels: 3.4±0.4 µg/dl (3 months) and 3.4±0.3 µg/dl (6 months). In contrast, there was no significant effect of L-carnitine supplementation after 1 month on serum albumin levels: 3.2±0.5 µg/dl before treatment and 3.3±0.4 µg/dl after 1 month (P=0.78). (B) Ammonia levels were significantly lower after 6 months of L-carnitine supplementation (56.5±31 µg/dl) compared with before treatment (101±40 µg/dl), and they showed a trend toward decreasing after 1 month (78±35 µg/dl; P=0.073) and 3 months (80±30 µg/dl; P=0.074) of therapy. *P<0.05.
Changes in Child-Pugh and MELD scores during L-carnitine supplementation in patients with cirrhosis. L-carnitine supplementation did not have any significant effect on Child-Pugh or MELD scores. (A) Child-Pugh scores were 7.3±1.4 before treatment, 7.2±1.5 after 1 month, 7.2±1.6 after 3 months and 7.2±1.9 after 6 months. (B) MELD scores were 6.6±0.9 before treatment, 6.7±0.9 after 1 month, 6.6±1.1 after 3 months and 6.8±1.5 after 6 months. MELD, Model For End-Stage Liver Disease.
Changes in total scores, physical subscale scores and mental subscale scores on the Chronic Fatigue Questionnaire after L-carnitine supplementation was initiated in patients with cirrhosis. (A) Total scores were significantly lower after 3 months (10.3±5) and 6 months (8.74±5) of L-carnitine supplementation compared with before treatment (14.7±6), whereas there was no significant change in the total scores after 1 month of therapy (14.5±6). (B) Scores on the physical subscale showed a decreasing trend 3 and 6 months after therapy initiation: 7.37±4.5 before treatment, 7.27±3.0 after 1 month, 5.17±3.0 after 3 months (P=0.057) and 4.37±4.0 after 6 months (P=0.07). (C) Scores on the mental subscale were significantly lower after 3 and 6 months of therapy: 7.42±3.0 before treatment, 7.37±3.0 after 1 month, 5.22±3.2 after 3 months and 4.43±3.1 after 6 months. *P<0.05.
Correlation of changes in total carnitine levels with changes in serum albumin levels and serum ammonia levels. (A) Changes in serum carnitine concentrations were positively correlated with changes in serum albumin levels; (B) but not with changes in serum ammonia levels.
Changes in d-ROM levels, BAP levels and the BAP/d-ROMs ratio during L-carnitine supplementation in patients with cirrhosis. (A) Serum d-ROM levels were significantly lower after 3 months (210.9±20.3 U.Carr) and 6 months (205.8±30.5 U.Carr) of L-carnitine supplementation compared with before treatment (225.2±50.6 U.Carr). In contrast, there was no significant effect of L-carnitine supplementation for 1 month on serum albumin levels (246.1±46.2 U.Carr). (B) L-carnitine supplementation did not have any significant effect on serum BAP levels: 2,100±322 µmol/l before treatment and 2,095±310 µmol/l after 1 month, 2,152±390 µmol/l after 3 months and 2,120±385 µmol/l after 6 months. (C) The d-ROMs/BAP ratio was significantly higher after 3 and 6 months of therapy: 8.5±2.0 before treatment, 9.3±2.2 after 1 month, 10.2±1.9 after 3 months and 10.3±1.5 after 6 months. *P<0.05. d-ROM, d-reactive oxygen metabolite; BAP, biological antioxidant potential.
Clinical and demographic characteristics of patients with cirrhosis.
Characteristics
Valuea
Age, years
71.0±8.4
Sex, male/female
19/11
Etiology, HBV/HCV/Alcohol/Others
2/14/9/5
Child-Pugh classification, A/B/C
10/18/2
Aspartate transaminase, IU/l
39.5±21.1
Alanine aminotransferase, IU/l
40.2±18.5
Alkaline phosphatase, IU/l
230±102
γ-glutamyl transpeptidase, U/l
31±30
Total bilirubin, mg/dl
1.5±0.8
Blood urea nitrogen, mg/dl
13±10
Total cholesterol, mg/dl
165±39
Triglyceride, mg/dl
90±52
Albumin, g/dl
3.3±0.5
Platelets, x104/µl
11.4±5.5
Prothrombin time, %
71.9±15.1
Ammonia, µg/dl
91±52
Total carnitine, µmol/l
66.5±12.8
Free carnitine, µmol/l
52.4±12.1
Acylcarnitine, µmol/l
14.1±3.7
aData are presented as the mean ± the standard error of the mean. HBV, hepatitis B virus; HCV, hepatitis C virus.